About vaccines

A nationwide study from Sweden investigates the effectiveness of COVID-19 vaccination against the risk of symptomatic infection, hospitalization, and death up to 9 months post-vaccination. // 16.11.2021

Researchers quantified the general VE achieved in the population of Norway, with the realized mixture of vaccine types, current population characteristics, and epidemic trajectory and directly estimated VE across vaccine types and age groups. // 16.11.2021

Researchers from University Medical Centre Utrecht have been investigating the efficiency of vaccines against the alpha variant in the Netherlands. // 15.11.2021

The current model is meant to provide an understanding of what might happen in the future, with periods of very low infection prevalence, interspersed between surges that have ever-lower peaks. // 15.11.2021

Exclusive: Oxfordshire-based Emergex gets go-ahead for trials in Switzerland for skin patch vaccine // 15.11.2021

We estimated vaccine effectiveness against onward transmission by comparing secondary attack rates among household members between vaccinated and unvaccinated index cases, based on source and contact tracing data collected when Delta variant was dominant. // 14.11.2021

While COVID-19 vaccines are available to all adults in England, new research suggests a disproportionate number of people who have not gotten the vaccine work in public-facing jobs. In addition, people who work from home were more likely to be vaccinated, suggesting ‘work from policies’ are limited in their effectiveness in preventing hospitalizations and COVID-19 deaths. // 15.11.2021

The Protective Immunity from T-cells to COVID-19 in Healthcare workers (PITCH) is a prospective, cohort, multi-center study enclosed within the SIREN study designed to assess the effectiveness of the BNT162b2 vaccine in healthcare workers. // 12.11.2021

Scientists from Florida, USA, have conducted a study to determine the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission from individuals with delta breakthrough infections. The findings reveal that delta breakthrough cases exhibit a relatively lower viral load compared to unvaccinated cases. // 14.11.2021

Researchers study individuals recruited in the ‘Virus Watch’ community cohort who had received their second dose of either ChAdOx1 or BNT162b2 vaccine. // 14.11.2021

// 7.9.2021

Background: Whether vaccine effectiveness against Coronavirus disease 2019 (Covid-19) lasts longer than 6 months is unclear. // 25.10.2021

This report describes mRNA COVID-19 vaccine recipients as having greater immunity from COVID-19 infection than previously infected, unvaccinated persons. // 5.11.2021

VACCINE EFFECTIVENESS - New research has found that double vaccinated people were three times less likely than unvaccinated people to test positive for the coronavirus. // 4.8.2021

Among fully vaccinated health care workers, the occurrence of breakthrough infections with SARS-CoV-2 was correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur. // 28.7.2021

The current surge in infections with the SARS-CoV-2 Delta variant has made it clear to health care workers and the public alike that fully vaccinated people remain at risk for SARS-CoV-2 infections. It is also apparent that breakthrough infections in fully vaccinated people can sometimes be serious.... // 4.11.2021

Real-world studies show Pfizer and AstraZeneca still offer strong protection against severe disease // 9.7.2021

A recent study looks at how mRNA vaccination affects hospitalization and ICU admission in COVID-19 breakthrough infections. // 12.11.2021

A group of scientists from Israel sought to evaluate the long-term effectiveness of the BioNTech/Pfizer mRNA BNT162b2 vaccine. // 11.11.2021

Researchers have been investigating which other proteins remain prevalent long enough for tests against them to be worthwhile. // 11.11.2021

The researchers evaluated immune response markers in a cross-section of people from the Indian state of West Bengal, including those vaccinated with either Covishield or Covaxin, the unvaccinated cohort, and the naturally infected. // 11.11.2021

Researchers at the University of Calgary Health Technology Assessment Unit investigated scientific evidence on various surveillance and testing methods to monitor the presence of the virus in a vaccinated population. // 10.11.2021

Next generation vaccines for Covid-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, concludes new research carried out by UCL scientists. // 10.11.2021

A team of UK-based scientists has recently estimated the prevalence of vaccine breakthrough infections and severe disease in a large number of individuals fully vaccinated against coronavirus disease 2019 (COVID-19) in England. // 10.11.2021

A team of researchers assessed antibody responses to the inactivated SARS-CoV-2 vaccine among vaccine recipients in Shenzhen, China. // 10.11.2021

A new study focused on the chronological changes in humoral and cell-mediated immune responses, during and after the BNT162b2 vaccine administration, among hospital workers of a national medical institution in Japan. // 10.11.2021

A register-based cohort study of the effectiveness of COVID-19 vaccines was performed to help decision-making on providing booster doses to social and healthcare workers (HCWs) like nurses, physicians, dentists, and other professionals in Finland. In addition, it estimated the vaccine effectiveness after the second dose. // 10.11.2021

A new study explores the potential of MV-based vaccines targeting the S protein of SARS-CoV-2. // 10.11.2021

Several vaccines have been rapidly developed to help control the COVID-19 pandemic, including the BNT162b2 vaccine (Pfizer/BioNTech). This severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine has been shown in both clinical trials and in the real world to be highly efficacious in preventing infection, symptoms, hospitalizations, severe disease, and death related to coronavirus disease (COVID-19). // 9.11.2021

A recent study reports the immunogenicity and safety of BNT162b2 and CoronaVac as the third dose in CoronaVac-immunized adults. // 8.11.2021